BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Inhibitor discovery offers promising new anticoagulant

July 1, 2015
By John Fox
HONG KONG – Chinese researchers have discovered a novel nonasaccharide molecule – a nine-unit sugar chain – with potent anticoagulant activity that could avoid adverse effects, paving the way for the development of better treatments for thromboembolic diseases, they reported in the June 22, 2015, early online issue of Proceedings of the National Academy of Sciences.
Read More

Mushroom minimizes mouse models of obesity

June 29, 2015
By John Fox
HONG KONG – An extract of a mushroom used in traditional Chinese medicine (TCM) reduces obesity in mice by altering the composition of the gut microbiota, suggesting it may prove useful for treating obesity and associated disorders in humans, according to a Taiwan study reported in the June 23, 2015, edition of Nature Communications.
Read More

Molecular modeling yields potential new Alzheimer's treatments

June 24, 2015
By John Fox
HONG KONG — Based on the findings of advanced molecular simulations, Japanese researchers have proposed potent new curcumin derivatives for the inhibition of amyloid-beta (Abeta) peptides, the main causal agents of Alzheimer's disease (AD). The findings could lead to new treatments for AD and other diseases.
Read More

Molecular modeling yields potential new Alzheimer's treatments

June 23, 2015
By John Fox
HONG KONG — Based on the findings of advanced molecular simulations, Japanese researchers have proposed potent new curcumin derivatives for the inhibition of amyloid-beta (Abeta) peptides, the main causal agents of Alzheimer's disease (AD). The findings could lead to new treatments for AD and other diseases.
Read More

Autophagy defect causes muscle loss in aging

June 17, 2015
By John Fox
HONG KONG – The discovery of a previously unknown autophagy defect associated with sarcopenia in mice could enhance the treatment or prevention strategies for managing the wasting condition in humans, suggest the findings of a study by Japanese researchers at Toyohashi University of Technology (TUT).
Read More

Autophagy defect causes muscle loss in aging

June 16, 2015
By John Fox
HONG KONG – The discovery of a previously unknown autophagy defect associated with sarcopenia in mice could enhance the treatment or prevention strategies for managing the wasting condition in humans, suggest the findings of a study by Japanese researchers at Toyohashi University of Technology (TUT).
Read More

New RNA-based sorting method yields purer cells

June 4, 2015
By John Fox
HONG KONG – New RNA-based switching biotechnology that detects and sorts cells derived from induced human pluripotent (iPS) cells using microRNAs (miRNAs) will enable production of purer cell populations with potentially better therapeutic outcomes, a study by Japanese researchers at the Center for iPS Cell Research and Application (CiRA) at Kyoto University has found.
Read More

New RNA-based sorting method yields purer cells

June 3, 2015
By John Fox
HONG KONG – New RNA-based switching biotechnology that detects and sorts cells derived from induced human pluripotent (iPS) cells using microRNAs (miRNAs) will enable production of purer cell populations with potentially better therapeutic outcomes, a study by Japanese researchers at the Center for iPS Cell Research and Application (CiRA) at Kyoto University has found.
Read More

New blood pressure finding could lead to new treatments

May 13, 2015
By John Fox
HONG KONG – The discovery of a novel mechanism for blood pressure (BP) regulation in a study by researchers at the Riken Brain Science Institute (BSI) in Wako, Japan, could have important implications for the control of elevated BP and may lead to the discovery of new antihypertensive medications.
Read More

New blood pressure finding could lead to new treatments

May 11, 2015
By John Fox
HONG KONG – The discovery of a novel mechanism for blood pressure (BP) regulation in a study by researchers at the Riken Brain Science Institute (BSI) in Wako, Japan, could have important implications for the control of elevated BP and may lead to the discovery of new antihypertensive medications.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing